-
1.发明申请N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors 失效N-半胱氨酸单取代的吲哚卡巴唑作为蛋白激酶抑制剂公开(公告)号：US20050075386A1
公开(公告)日：2005-04-07
申请号：US10496505
申请日：2002-12-04
申请人： Heidi Sahagun-Krause , Olivier Du Boullay , Valerie Du Boullay , Laura Casiraghi , Hans-Wolfgang Klafki , Pierfausto Seneci , Tobias Braxmeier , Silvia Muller , Wolfgang Frohner , Barbara Monse , Sandra Gordon , Hanno Roder
发明人： Heidi Sahagun-Krause , Olivier Du Boullay , Valerie Du Boullay , Laura Casiraghi , Hans-Wolfgang Klafki , Pierfausto Seneci , Tobias Braxmeier , Silvia Muller , Wolfgang Frohner , Barbara Monse , Sandra Gordon , Hanno Roder
IPC分类号： A61K31/407 , A61K31/4192 , A61P3/10 , A61P25/00 , A61P25/28 , A61P35/00 , A61P43/00 , C07D487/14
CPC分类号： C07D487/14
摘要： This invention relates to N-carbacycle monosubstituted indolocarbazole compounds. Furthermore, this invention relates to medicaments comprising N-carbacycle monosubstituted indolocarbazoles compounds and the use of such compounds for treating non-insulin dependent diabetes mellitus, acute stroke and other neurotraumatic injuries, for treating diabetes mellitus, as a chemotherapeutic for the treatment of various malignant diseases, for treating diseases caused by malfunctioning of specific signaling pathways, and for treating neurodegenerative diseases such as for example Alzheimer's disease.
摘要翻译： 本发明涉及N-碳酸酯单取代的吲哚咔唑化合物。 此外，本发明涉及包含N-碳酸酯单取代的吲哚并唑化合物的药物，以及这些化合物用于治疗非胰岛素依赖性糖尿病，急性中风和其他神经创伤性损伤的用途，用于治疗糖尿病，作为治疗各种恶性肿瘤的化学治疗剂 疾病，用于治疗由特异性信号通路异常引起的疾病，以及用于治疗神经变性疾病例如阿尔茨海默氏病。
-
公开(公告)号：US20070232584A1
公开(公告)日：2007-10-04
申请号：US11597771
申请日：2005-05-26
申请人： Hanno Roder
发明人： Hanno Roder
IPC分类号： A61K31/551 , A61K31/553 , A61P25/16 , A61P25/28 , C07D273/06 , C12Q1/18 , G01N33/15 , G01N33/53
CPC分类号： A61K31/553
摘要： The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurode-generative and/or dementing illness driven by the molecular pathology of microtubule-associate tau such as Alzheimer's disease, frontal lobe dementia, Pick's disease, Parkinson disease with dementia, corticobasal degeneration, argyrophilic grains disease, or supranuclear palsy. A method for treating or preventing such illnesses is also disclosed. Furthermore, methods for the identification of efficacious inhibitors of neurofibrillary degeneration, and methods for the determination of an appropriate dosage of an inhibitor of the PHF-type tau hyperphosphorylation for the treatment of a condition characterized by neurofibrillary pathology are described.
摘要翻译： 本发明涉及通式（1）的特定吲哚并咔唑化合物或其药学上可接受的盐的用途，用于制备用于预防或治疗由以下物质驱动的神经发生和/或痴呆疾病的药物组合物： 微管相关性tau的分子病理学如阿尔茨海默氏病，额叶痴呆，皮克病，帕金森病与痴呆，皮质基底变性，嗜ilic性颗粒病或核核性麻痹。 还公开了治疗或预防这种疾病的方法。 此外，描述了用于鉴定神经原纤维变性的有效抑制剂的方法，以及用于确定用于治疗以神经原纤维病理学为特征的病症的PHF型tau高度磷酸化的抑制剂的适当剂量的方法。
-
公开(公告)号：US20080255087A1
公开(公告)日：2008-10-16
申请号：US11956841
申请日：2007-12-14
申请人： Hanno Roder
发明人： Hanno Roder
IPC分类号： A61K31/553 , C07D273/06 , A61P35/00
CPC分类号： A61K31/70 , A61K31/7008 , A61K31/7056
摘要： The present invention relates to the use of specific compounds related to the indolocarbazole K252a, for the preparation of pharmaceutical compositions for the treatment of various forms of cancer.
摘要翻译： 本发明涉及用于制备用于治疗各种形式的癌症的药物组合物的与吲哚并咔唑K252a有关的具体化合物的用途。
-
公开(公告)号：US08022056B2
公开(公告)日：2011-09-20
申请号：US11956841
申请日：2007-12-14
申请人： Hanno Roder
发明人： Hanno Roder
IPC分类号： A61K31/33
CPC分类号： A61K31/70 , A61K31/7008 , A61K31/7056
摘要： The present invention relates to the use of specific compounds related to the indolocarbazole K252a, for the preparation of pharmaceutical compositions for the treatment of various forms of cancer.
摘要翻译： 本发明涉及用于制备用于治疗各种形式的癌症的药物组合物的与吲哚并咔唑K252a有关的具体化合物的用途。
-
公开(公告)号：US08003631B2
公开(公告)日：2011-08-23
申请号：US11597771
申请日：2005-05-26
申请人： Hanno Roder
发明人： Hanno Roder
CPC分类号： A61K31/553
摘要： The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurodegenerative and/or dementing illness driven by the molecular pathology of microtubule-associate tau such as Alzheimer's disease, frontal lobe dementia, Pick's disease, Parkinson disease with dementia, corticobasal degeneration, argyrophilic grains disease, or supranuclear palsy. A method for treating or preventing such illnesses is also disclosed. Furthermore, methods for the identification of efficacious inhibitors of neurofibrillary degeneration, and methods for the determination of an appropriate dosage of an inhibitor of the PHF-type tau hyperphosphorylation for the treatment of a condition characterized by neurofibrillary pathology are described.
摘要翻译： 本发明涉及通式（1）的特定吲哚并咔唑化合物或其药学上可接受的盐在制备用于预防或治疗由分子驱动的神经变性和/或蜕皮疾病的药物组合物中的用途 微管相关性tau的病理学如阿尔茨海默病，额叶痴呆，皮克病，帕金森病与痴呆，皮质基底变性，嗜酸粒细胞病或核核性麻痹。 还公开了治疗或预防这种疾病的方法。 此外，描述了用于鉴定神经原纤维变性的有效抑制剂的方法，以及用于确定用于治疗以神经原纤维病理学为特征的病症的PHF型tau高度磷酸化的抑制剂的适当剂量的方法。
-
公开(公告)号：US20120202789A1
公开(公告)日：2012-08-09
申请号：US13224722
申请日：2011-09-02
申请人： Hanno Roder
发明人： Hanno Roder
IPC分类号： A61K31/553 , A61P35/02 , A61P35/00
CPC分类号： A61K31/70 , A61K31/7008 , A61K31/7056
摘要： The present invention relates to the use of specific compounds related to the indolocarbazole K252a, for the preparation of pharmaceutical compositions for the treatment of various forms of cancer.
摘要翻译： 本发明涉及用于制备用于治疗各种形式的癌症的药物组合物的与吲哚并咔唑K252a有关的具体化合物的用途。
-
7.发明授权Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer 失效用于治疗神经变性疾病和癌症的吲哚咔唑衍生物公开(公告)号：US06541468B1
公开(公告)日：2003-04-01
申请号：US09382539
申请日：1999-08-25
IPC分类号： A61K3155
CPC分类号： C07D487/16 , C07D487/22
摘要： Novel indolocarbazole derivatives potentially useful for the treatment of dementias characterized by tau hyperphosphorylation [Alzheimer's disease (AD), frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotising panencephalitis (SSPE) as a late complication of viral infections in the CNS], and cancer.
摘要翻译： 新型吲哚并咔唑衍生物可用于治疗以tau过度磷酸化为特征的痴呆症[阿尔茨海默病（AD），额叶变性（FLD），嗜酸性粒细胞病，亚急性硬化性全脑炎（SSPE）作为CNS病毒感染的晚期并发症] 和癌症。
-
8.发明授权Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer 失效用于治疗神经变性疾病和癌症的吲哚咔唑衍生物
公开(公告)号：US6013646A
公开(公告)日：2000-01-11
申请号：US109131
申请日：1998-07-02
IPC分类号： A61K31/551 , A61P25/28 , A61P35/00 , A61P43/00 , C07D487/16 , C07D487/22 , A61K31/55 , C07D487/00 , C07D491/00
CPC分类号： C07D487/16 , C07D487/22
摘要： Novel indolocarbazole derivatives potentially useful for the treatment of dementias characterized by tau hyperphosphorylation [Alzheimer's disease (AD), frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) as a late complication of viral infections in the CNS], and cancer.
摘要翻译： 新型吲哚咔唑衍生物可用于治疗以tau高磷酸化为特征的痴呆症[阿尔茨海默病（AD），额叶变性（FLD），嗜酸粒细胞病，亚急性发育性全脑炎（SSPE）作为CNS病毒感染的晚期并发症] 和癌症。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.038 秒)
